



vaccines



an Open Access Journal by MDPI

The Development of SARS-CoV-2 Vaccines Using Various Strategies

Guest Editor:

Dr. Tokiko Watanabe

Department of Molecular
Virology Research Institute for
Microbial Diseases, Osaka
University, Osaka 565-0871,
Japan

Deadline for manuscript
submissions:

closed (20 April 2022)

Message from the Guest Editor

SARS-CoV-2, which emerged at the end of 2019, is still rampant around the world, causing enormous health and economic damage. The development of SARS-CoV-2 vaccines has proceeded at an unprecedented pace, and several vaccines have already been approved and administered in many countries. However, despite expectations that global vaccination will lead to the end of the pandemic, variants possessing amino acid substitutions in the antigenic sites of the SARS-CoV-2 spike protein continue to emerge all over the world, raising concerns about the effectiveness of the current vaccines. Therefore, it is important to continue to develop vaccines using strategies that improve our preparedness for these emerging variants. In this Special Issue, we seek articles (both reviews and original research) discussing the development of SARS-CoV-2 vaccines using various strategies.



mdpi.com/si/95124

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com